

## DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"NEW PROCESS"

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 25 October 2004  
and was amended on

as Serial No. PCT/EP2004/012093  
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
0325055.2	GB	27 October 2003	YES

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Philippe ADAM

Inventor's Signature: \_\_\_\_\_

Date: 09 mar. 2005

Residence: MAXEVILLE, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Olivier LUDEMANN-HOMBOURGER

Inventor's Signature: \_\_\_\_\_

Date: 10 March 2005

Residence: POMPEY, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Elias NDZIE

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: VELAINE EN HAYE, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: David Simon ROSS

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: TONBRIDGE, KENT, UNITED KINGDOM

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Mireille SCHAEFFER

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: POMPEY, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Elias NDZIE

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: VELAINE EN HAYE, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: David Simon ROSS

Inventor's Signature: \_\_\_\_\_ *DRS*

Date: 8<sup>th</sup> March 2005

Residence: TONBRIDGE, KENT, UNITED KINGDOM

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Mireille SCHAEFFER

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: POMPEY, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Elias NDZIE

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: VELAINE EN HAYE, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: David Simon ROSS

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: TONBRIDGE, KENT, UNITED KINGDOM

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Mireille SCHAEFFER

Inventor's Signature:  \_\_\_\_\_

Date: 14/03/05

Residence: POMPEY, FRANCE  
PLOBSCHEIM

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Cristina SUTEU

Inventor's Signature: CR

Date: 4/03/05

Residence: ILLKIRCH, FRANCE

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

A/058140

10/577417  
AP20F1371PCT/PTO 26 APR 2006

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**STATEMENT UNDER 37 CFR 3.73(b)****Applicant/Patent Owner: SmithKline Beecham Corporation****International Application No./Patent No.:** \_\_\_\_\_ **Filed/Issue Date:** \_\_\_\_\_**Entitled: NEW PROCESS****SmithKline Beecham Corporation, a corporation, states that it is:**

1. ☒ the assignee of the entire right, title, and interest; or
  2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ % in the patent application/patent identified above by virtue of either;
    - A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which copy thereof is attached.
    - OR
    - B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
      1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
      2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
      3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.  
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

**04 MAR 2005**

Signature

Date

Peter John GIDDINGS

+44 20 8047 4414

Printed or Typed Name

Telephone Number

Attorney and Authorised Official

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## ASSIGNMENT

WHEREAS I/WE, **David Simon ROSS of Tonbridge, Kent, GB** (hereinafter called "the inventor(s)") have invented or discovered "**NEW PROCESS**" (hereinafter called "the invention") for which a patent application No. **0325055.2** was filed on **27 October 2003** in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

PCT/EP2004/012093 filed 25 October 2004

**WHEREAS** the invention, being made in the course of my employment, belongs to my/our employer, namely **GLAXOSMITHKLINE SERVICES UNLIMITED** a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

**WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**, a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from **GLAXOSMITHKLINE SERVICES UNLIMITED** the whole right, title and interest in and to the invention and the application, and

**GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** have authorised and requested my/our making the application, and

**WHEREAS SMITHKLINE BEECHAM CORPORATION** a corporation organised and existing under and by virtue of the laws of the State of Pennsylvania and having its principal place of business at One Franklin Plaza, P O Box 7929, Philadelphia, Pennsylvania 19101-7929, USA, is desirous of acquiring from **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** the whole




right, title and interest in and to the invention and the application in respect of the United States of America;

**NOW, THEREFORE**, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXOSMITHKLINE SERVICES UNLIMITED** of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXOSMITHKLINE SERVICES UNLIMITED**. **GLAXOSMITHKLINE SERVICES UNLIMITED** in turn hereby assigns and transfers to **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** in turn hereby assigns and transfers to **SMITHKLINE BEECHAM CORPORATION** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to **SMITHKLINE BEECHAM CORPORATION**.

**AND GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are


necessary or desirable to more effectually secure to and vest in **SMITHKLINE BEECHAM CORPORATION**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

**IN WITNESS** whereof and with effect from **27 October 2003** the inventor(s) and **Peter John GIDDINGS** as Attorney of both **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** by virtue of Powers of Attorney granted by **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** respectively have hereunto set their respective hands.

  
\_\_\_\_\_  
SIGNED by David Simon ROSS

Date: ..... 8<sup>th</sup> March 2005 .....

SIGNED by **Peter John GIDDINGS** as the Attorney of each of **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**:

  
-----

15 MAR 2005  
Date: .....

**ASSIGNMENT**

WHEREAS **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** (hereinafter "**GSK R&D**"), a company incorporated in England and Wales, whose registered address is 980 Great West Road, Brentford, Middlesex, UK, TW8 9GS, and **NOVASEP SAS**, a company incorporated in France, whose registered address is Site Eiffel Boulevard de la Moselle BP 50 54340 Pompey France (hereinafter "**NOVASEP SAS**") entered into an Evaluation Agreement (hereinafter "the Evaluation Agreement") dated 25<sup>th</sup> March 2002, pursuant to which any Results and related Intellectual Property Rights (both as defined in the Evaluation Agreement) belong to **GSK R&D**;

WHEREAS We, **Olivier LUDEMANN-HOMBOURGER, 62 rue du Maréchal de Lattre de Tassigny 54340 POMPEY FRANCE; Elias NDZIE, 14 rue du Chauxfour 54840 VELAIN EN HAYE FRANCE and Philippe ADAM 42 rue Justice 54320 MAXEVILLE FRANCE** (hereinafter called "**the co-inventors**") have, as a result of work carried out pursuant to the Evaluation Agreement, jointly invented or discovered subject matter concerning a "Novel Process" (hereinafter called "the invention") for which UK Patent Application No. 0325055.2 was filed on 27 October 2003 and for which an International Patent Application is to be filed claiming priority from the UK Patent Application and designating *inter alia* the United States of America (hereinafter called "the applications");

WHEREAS **the co-inventors, NOVASEP SAS and GSK R&D** hereby authorize and request that the filing date and the International Patent Application number, when known, be inserted here in parentheses:

(PCT/EP2004/012093 filed 25 October 2004);

WHEREAS **the co-inventors, NOVASEP SAS and GSK R&D** each acknowledge their agreement to the filing of the applications;

WHEREAS the whole right, title and interest of **the co-inventors** in and to the invention and the applications belongs to **NOVASEP SAS** by virtue of a contract of employment of **the co-inventors** with **NOVASEP SAS**;

WHEREAS WE, **SMITHKLINE BEECHAM CORPORATION**, a company incorporated in Pennsylvania, United States of America, whose registered address is One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America, are desirous of acquiring from **GSK R&D** the whole right, title and interest in and to the invention and the applications, including in respect of the United States of America.

NOW THEREFORE, to all whom it may concern be it known that we **the co-inventors** hereby confirm the ownership by **NOVASEP SAS** of each of our whole right, title and interest in and to the invention and the applications and if, under the law of the United States of America we **the co-inventors** each have any ownership right, title and interest in and to the invention and the applications (which we do not believe to be the case and claim no ownership right, title or interest in and to the invention and the applications), we **the co-inventors** each nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the applications to **NOVASEP SAS**.

Pursuant to the Evaluation Agreement, **NOVASEP SAS** hereby assigns and transfers to **GSK R&D** its whole right, title and interest in and to the invention and the applications, including without limitation in and throughout the United States of America, and in and to any priority rights in respect of the invention and the applications, and in and to any divisional application, continuation or continuation-in-part application, and in and to any extension or re-issue, and in and to any patent in the world arising therefrom, including in the United States of America.

**GSK R&D** in turn hereby assigns and transfers to **SMITHKLINE BEECHAM CORPORATION** its whole right, title and interest in and to the invention and the applications, including without limitation in and throughout the United States of America, and in and to any priority rights in respect of the invention and the applications, and in and to any divisional application, continuation or continuation-in-part application, and in and to any extension or re-issue, and in and to any patent in the world arising there from, including in the United States of America; and we **the co-inventors, NOVASEP SAS and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any such patent, including in the United States of America, be issued to **SMITHKLINE BEECHAM CORPORATION**.

**NOVASEP SAS** and **the co-inventors** each for themselves and their executors and legal representatives hereby acknowledge that these assignments are made following receipt of good consideration, the sufficiency of which is confirmed, and agree to provide reasonable information and make execute and deliver any and all other reasonable instruments in writing, and any and all further reasonable acts, applications, papers, affidavits, assignments and other documents which may be necessary or desirable to more effectually secure to and vest in **SMITHKLINE BEECHAM CORPORATION** its successors and assigns, the whole right, title and interest in and to the invention and the applications hereby assigned and transferred, including in respect of the United States of America.


**IN WITNESS** whereof and with effect from 27 October 2003, **the co-inventors**, and **NOVASEP SAS**, and **GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED**, and **SMITHKLINE BEECHAM CORPORATION**, by virtue of Powers of Attorney granted to its duly authorised officers, have hereunto set their respective hands.

(1) **SIGNED by Olivier LUDEMANN-HOMBOURGER:**




Date: <sup>th</sup> 14 October 2004

In the presence of




(Jean BLEHAUT):

(2) **SIGNED by Elias NDZIE:**



Date: <sup>th</sup> 14 October 2004

In the presence of




(Jean BLEHAUT):


(3) **SIGNED by Philippe ADAM:**



Date: <sup>th</sup> 14 October 2004

In the presence of  (Jean BLEHAUT):

(4) SIGNED by NOVASEP SAS:




Date: October 14, 2004

Authorised Official

Name: Jean BLEHAUT  
Capacity: President

(5) SIGNED by GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED:




Date: 10 NOV 2004

Authorised Official

Name: Peter John GIDDINGS  
Capacity: Attorney and Authorised Official

(6) SIGNED by SMITHKLINE BEECHAM CORPORATION:



Date: 10<sup>th</sup> November, 2004

Authorised Official

Name: Arthur William Russell TYRRELL  
Capacity: Attorney and Authorised Official

**ASSIGNMENT**

WHEREAS **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** (hereinafter "**GSK R&D**"), a company incorporated in England and Wales, whose registered address is 980 Great West Road, Brentford, Middlesex, UK, TW8 9GS, and **CHIRAL TECHNOLOGIES S.A.S**, a company incorporated in France, whose registered address is Parc d'Innovation, Bd. Gonthier d'Andernach, 67400 Illkirch Cedex, France, entered into an Evaluation Agreement (hereinafter "the Evaluation Agreement") dated 5<sup>th</sup> March 2002, pursuant to which any Results and related Intellectual Property Rights (both as defined in the Evaluation Agreement) belong to **GSK R&D**;

WHEREAS We, **Mireille Schaeffer, 36c, rue du Général Leclerc, F-67115, Plobsheim** and **Cristina Suteu, 14 rue du Lieutenant Homps, F-67400, Illkirch** (hereinafter called "**the co-inventors**") have, as a result of work carried out pursuant to the Evaluation Agreement, jointly invented or discovered subject matter concerning a "Novel Process" (hereinafter called "the invention") for which UK Patent Application No. 0325055.2 was filed on 27 October 2003 and for which an International Patent Application is to be filed claiming priority from the UK Patent Application and designating *inter alia* the United States of America (hereinafter called "the applications");

WHEREAS **the co-inventors, CHIRAL TECHNOLOGIES S.A.S and GSK R&D** hereby authorize and request that the filing date and the International Patent Application number, when known, be inserted here in parentheses:

(PCT/ EP2004/012093 filed 25 October 2004);

WHEREAS **the co-inventors, CHIRAL TECHNOLOGIES S.A.S and GSK R&D** each acknowledge their agreement to the filing of the applications;

WHEREAS the whole right, title and interest of **the co-inventors** in and to the invention and the applications belongs to **CHIRAL TECHNOLOGIES S.A.S** by virtue of a contract of employment of **the co-inventors** with **CHIRAL TECHNOLOGIES**;

WHEREAS WE, **SMITHKLINE BEECHAM CORPORATION**, a company incorporated in Pennsylvania, United States of America, whose registered address is

One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America, are desirous of acquiring from **GSK R&D** the whole right, title and interest in and to the invention and the applications, including in respect of the United States of America.

NOW THEREFORE, to all whom it may concern be it known that we **the co-inventors** hereby confirm the ownership by **CHIRAL TECHNOLOGIES S.A.S** of each of our whole right, title and interest in and to the invention and the applications and if, under the law of the United States of America we **the co-inventors** each have any ownership right, title and interest in and to the invention and the applications (which we do not believe to be the case and claim no ownership right, title or interest in and to the invention and the applications), we **the co-inventors** each nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the applications to **CHIRAL TECHNOLOGIES S.A.S**.

Pursuant to the Evaluation Agreement, **CHIRAL TECHNOLOGIES S.A.S** hereby assigns and transfers to **GSK R&D** its whole right, title and interest in and to the invention and the applications, including without limitation in and throughout the United States of America, and in and to any priority rights in respect of the invention and the applications, and in and to any divisional application, continuation or continuation-in-part application, and in and to any extension or re-issue, and in and to any patent in the world arising therefrom, including in the United States of America.


**GSK R&D** in turn hereby assigns and transfers to **SMITHKLINE BEECHAM CORPORATION** its whole right, title and interest in and to the invention and the applications, including without limitation in and throughout the United States of America, and in and to any priority rights in respect of the invention and the applications, and in and to any divisional application, continuation or continuation-in-part application, and in and to any extension or re-issue, and in and to any patent in the world arising therefrom, including in the United States of America; and we **the co-inventors**, **CHIRAL TECHNOLOGIES S.A.S** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any such patent, including in the United States of America, be issued to **SMITHKLINE BEECHAM CORPORATION**.



**CHIRAL TECHNOLOGIES S.A.S** and the co-inventors each for themselves and their executors and legal representatives hereby acknowledge that these assignments are made following receipt of good consideration, the sufficiency of which is confirmed, and agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **SMITHKLINE BEECHAM CORPORATION** its successors and assigns, the whole right, title and interest in and to the invention and the applications hereby assigned and transferred, including in respect of the United States of America.

**IN WITNESS** whereof and with effect from 27 October 2003, the co-inventors, and **CHIRAL TECHNOLOGIES S.A.S**, and **GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED**, and **SMITHKLINE BEECHAM CORPORATION**, by virtue of Powers of Attorney granted to its duly authorised officers, have hereunto set their respective hands.


(1) **SIGNED by Mireille Schaeffer**



Date: 19/10/04

In the presence of WEBER Judith (PRINT NAME):


(2) **SIGNED by Cristina Suteu**



Date: 19/10/04

In the presence of WEBER Judith (PRINT NAME):

(3) SIGNED by CHIRAL TECHNOLOGIES S.A.S :




Date: 14/10/2004

Authorised Official

Name: Dieter Heckmann  
Capacity: President

(4) SIGNED by GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED:




Date: 10 NOV 2004

Authorised Official

Name: Peter John GIDDINGS  
Capacity: Attorney and Authorised Official

(5) SIGNED by SMITHKLINE BEECHAM CORPORATION:



Date: 10<sup>th</sup> November, 2004

Authorised Official

Name: Arthur William Russell TYRRELL  
Capacity: Authorised Official and Attorney

## **Power of Attorney**

**BY THIS POWER OF ATTORNEY** given this 23<sup>rd</sup> day of February two thousand and five **SMITHKLINE BEECHAM CORPORATION**, a company incorporated in Pennsylvania (Registration No. 3330395) and having its registered office at One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America, (hereinafter called "the Company"), **HEREBY** appoints all and any of its Directors, Secretary and Assistant Secretary for the time being, and **DAVID ROBERTS, PETER JOHN GIDDINGS, ARTHUR WILLIAM RUSSELL TYRRELL, HUGH BAINFORDE DAWSON, WENDY ANNE FILLER, MICHAEL JOHN STOTT, PETER I. DOLTON, HELEN KAYE QUILLIN, MARCUS JONATHAN WILLIAM DALTON, CHARLES M. KINZIG, STEPHEN VENETIANER, THEODORE R. FURMAN, MARY E. MCCARTHY, EDWARD R. GIMMI, CHARLES EDWARD DADSWELL, ROBERT H. BRINK, and FRANK P. GRASSLER** jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys") on behalf and in the name of the Company or otherwise to do, perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto; utility models; copyrights; trademark registrations; trademarks; trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

1. In any country or countries or jurisdiction in any part of the world to make application or cause application to be made for the grant or issue or transfer to the Company or registration in its name of Intellectual Property Rights and to take all steps necessary for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended or extended.
2. As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any Intellectual Property Rights or the right to and interest in any inventions to be the subject of Intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
3. As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sub-licences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.
4. To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise responsible for the registration or protection of trademarks, trade names, trade dress, logos, design rights or designs for the purpose of best protecting or ensuring the co-existence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.
5. To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.


6. For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent, including trademark and patent agents and attorneys, to act on behalf of the Company.
7. To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.
8. To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.
9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.
10. This Power of Attorney shall expire on December 31, 2006

**AND THE COMPANY HEREBY RATIFIES** and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained

**AND THE COMPANY HEREBY DECLARES** that all instruments executed under and by virtue of this Power shall be as valid and effectual as if sealed by the Common Seal of the Company.

**IN WITNESS** whereof **SMITHKLINE BEECHAM CORPORATION** has caused its Common Seal to be hereunto affixed the day and year first before written

The **COMMON SEAL** of )  
**SMITHKLINE BEECHAM CORPORATION** )  
was hereto affixed in the presence of: )

  
\_\_\_\_\_  
Donald F. Parman  
Vice President and Secretary

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	
	<b>Filing Date</b>	25 October 2004
	<b>First Named Inventor</b>	Philippe ADAM
	<b>Title</b>	NEW PROCESS
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	PB60563

I hereby appoint:

☒ Practitioners associated with the Customer Numbers. 23347

Or

☐ Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

Or

☒ The address associated with Customer Number 23347

Or

☐ Firm or Individual Name:

Address:

Address:

City:

State:

Zip:

Country:

Telephone:

Fax:

I am the:

☐ Applicant/Inventor:☒ Assignee or record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature:	Date: 04 MAR 2005
Name: Peter John GIDDINGS	Telephone: +44 20 8047 4414
Title and Company: Attorney and Authorised Official, SmithKline Beecham Corporation	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.	
<input type="checkbox"/> *Total of: forms are submitted.	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.